Genera Biosystems Ltd (ASX:GBI) has been granted a trading halt this morning pending a co-marketing partnering agreement with a major IVD company in relation to its AmpaSand® molecular diagnostic testing menu. Genera is a molecular diagnostics company which develops, manufactures and distributes advanced PCR molecular diagnostics tests. The AmpaSand® testing platform can detect up to 125 target analytes in a single-well of a reaction plate. The halt will remain in place until the opening of trade on Wednesday 29th November 2017, or earlier if an announcement is made to the market.
